ReviewCureus2025
Dorsal Root Ganglion Stimulation for Postherpetic Neuralgia: A Pilot Scoping Review of the Current Evidence.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spinal Cord Stimulation and DREZ Lesioning for Refractory Postherpetic Neuralgia: An Exploratory Case Series.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review synthesizes current evidence regarding the use of dorsal root ganglion (DRG) stimulation, a form of pain neuromodulation, for managing postherpetic neuralgia (PHN), a debilitating chronic neuropathic pain syndrome arising from herpes zoster virus infection. Comprehensive searches across multiple databases (MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library) for studies published from 2010 onward were supplemented by manual reference checks and gray literature review. Inclusion criteria encompassed adults with PHN (pain persisting ≥ three months post-rash onset) treated with DRG stimulation involving varying lead placements and stimulation techniques. Two independent reviewers screened articles and extracted data, resolving disagreements through consensus or a third reviewer, with a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram documenting study selection, resulting in 23 included studies after screening 117 initial references. Extracted data revealed variability in DRG stimulation techniques (percutaneous vs. surgical lead placement) and parameters (tonic, burst, high-frequency), with reported outcomes including pain scores, quality of life, opioid use, and complications. While case series support DRG efficacy for PHN, studies are limited by small sample sizes and a lack of prospective or randomized trials focused exclusively on PHN. Many studies included mixed-pain populations, complicating direct comparisons. Broader neuromodulation evidence suggests DRG may cause fewer paresthesias than spinal cord stimulation (SCS). Some studies indicate DRG may be more effective for other neuropathic pain types than for PHN. This review identifies significant variability and substantial gaps in the literature, notably the absence of rigorous randomized controlled trials and studies focusing solely on PHN, underscoring the need for standardized protocols and targeted clinical trials. Although DRG stimulation shows potential for managing PHN, its comparative effectiveness relative to other pain etiologies warrants further investigation to refine treatment approaches and optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.